메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 24, Issue 1, 2006, Pages 4-5
New targets, therapies, and toxicities: Lessons to be learned
Author keywords

[No Author keywords available]
Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB; TAXANE DERIVATIVE; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;
EID: 33644848511     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.2408     Document Type: Editorial
Times cited : (16)
References (7)
  • 1
    • 33644847440 scopus 로고    scopus 로고
    • Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    • Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 25-35
    • Faivre, S.1    Delbaldo, C.2    Vera, K.3
  • 2
    • 12244301581 scopus 로고    scopus 로고
    • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
    • Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
    • (2003) Clin Cancer Res , vol.9 , pp. 327-337
    • Mendel, D.B.1    Laird, A.D.2    Xin, X.3
  • 3
    • 23844480013 scopus 로고    scopus 로고
    • Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma
    • suppl; abstr 4508
    • Motzer RJ, Rini BI, Michaelson MD, et al; Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. J Clin Oncol 24:380, 2005 (suppl; abstr 4508)
    • (2005) J Clin Oncol , vol.24 , pp. 380
    • Motzer, R.J.1    Rini, B.I.2    Michaelson, M.D.3
  • 4
    • 28044467635 scopus 로고    scopus 로고
    • Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST
    • suppl; abstr 4000
    • Demetri GD, van Oosterom AT, Blackstein M, et al: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J Clin Oncol 24:308, 2005 (suppl; abstr 4000)
    • (2005) J Clin Oncol , vol.24 , pp. 308
    • Demetri, G.D.1    van Oosterom, A.T.2    Blackstein, M.3
  • 5
    • 20044382799 scopus 로고    scopus 로고
    • Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
    • Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 965-972
    • Strumberg, D.1    Richly, H.2    Hilger, R.A.3
  • 6
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3
  • 7
    • 16544380415 scopus 로고    scopus 로고
    • Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST
    • Ratain MJ, Eckhardt SG: Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 22:4442-4445, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 4442-4445
    • Ratain, M.J.1    Eckhardt, S.G.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.